Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician …

…, M Cornalba, M Soubrier, N Roux, O Brocq… - Annals of the …, 2022 - ard.bmj.com
Objectives To describe the safety of vaccines against SARS-CoV-2 in people with
inflammatory/autoimmune rheumatic and musculoskeletal disease (I-RMD). Methods Physician-…

Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial

W Sterry, JP Ortonne, B Kirkham, O Brocq, D Robertson… - Bmj, 2010 - bmj.com
Objectives To compare the efficacy over 12 weeks of two different etanercept regimens in
treating the skin manifestations of psoriasis in patients who also have psoriatic arthritis and to …

Non–TNF-targeted biologic vs a second anti-TNF drug to treat rheumatoid arthritis in patients with insufficient response to a first anti-TNF drug: a randomized clinical …

JE Gottenberg, O Brocq, A Perdriger, S Lassoued… - Jama, 2016 - jamanetwork.com
Importance One-third of patients with rheumatoid arthritis show inadequate response to tumor
necrosis factor α (TNF-α) inhibitors; little guidance on choosing the next treatment exists. …

Overview of STING-associated vasculopathy with onset in infancy (SAVI) among 21 patients

…, N Jeremiah, A Belot, V Bondet, O Brocq… - The Journal of Allergy …, 2021 - Elsevier
Background Gain-of-function mutations in STING1 underlie a type I interferonopathy termed
SAVI (STING-associated vasculopathy with onset in infancy). This severe disease is variably …

Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: results of the multicentre non-inferiority randomised open-label …

…, J Morel, E Dernis, P Gaudin, O Brocq… - Annals of the …, 2016 - ard.bmj.com
Tumour necrosis factor (TNF)-blocker tapering has been proposed for patients with rheumatoid
arthritis (RA) in remission. Objective The trial aims to compare the effect of progressive …

Effect of discontinuing TNFα antagonist therapy in patients with remission of rheumatoid arthritis

O Brocq, E Millasseau, C Albert, C Grisot, P Flory… - Joint Bone Spine, 2009 - Elsevier
OBJECTIVE: The objective of this study was to determine the time to relapse after tumor
necrosis factor α (TNFα) antagonist discontinuation in patients with remission of rheumatoid …

Outcome of osteoporotic pelvic fractures: an underestimated severity. Survey of 60 cases

…, CH Roux, J Testa, C Albert, M Chassang, O Brocq… - Joint Bone Spine, 2008 - Elsevier
The aim is to describe the characteristics of osteoporotic pelvic fractures and their outcome.
We recorded clinical and biological characteristics of 60 osteoporotic pelvic fractures …

[HTML][HTML] Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium

…, J Avouac, M Birchler, Y Bouhnik, O Brocq… - PLoS …, 2020 - journals.plos.org
Background Biopharmaceutical products (BPs) are widely used to treat autoimmune
diseases, but immunogenicity limits their efficacy for an important proportion of patients. Our …

A pilot study on the recovery from paresis after lumbar disc herniation

…, C Bonnet, E Houvenagel, S Hary, O Brocq… - Spine, 2002 - journals.lww.com
Background. Although the existence of a motor defect in discogenic sciatica is a sign of
severity, the literature does not provide evidence for an immediate requirement for surgery. …

Septic knee arthritis after intra-articular hyaluronate injection: two case reports

C Albert, O Brocq, D Gerard, C Roux, L Euller-Ziegler - Joint Bone Spine, 2006 - Elsevier
Intraarticular sodium hyaluronate injection to treat osteoarthritis is associated with minor
side effects. Infections seem uncommon. We report two cases of septic knee arthritis. One …